UroGen Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.

About URGN

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. 

CEO
Elizabeth Barrett
CEOElizabeth Barrett
Employees
291
Employees291
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
2004
Founded2004
Employees
291
Employees291

URGN Key Statistics

Market cap
2.99B
Market cap2.99B
Price-Earnings ratio
-24.13
Price-Earnings ratio-24.13
Dividend yield
Dividend yield
Average volume
1.12M
Average volume1.12M
High today
$49.60
High today$49.60
Low today
$47.67
Low today$47.67
Open price
$49.60
Open price$49.60
Volume
859.71K
Volume859.71K
52 Week high
$49.67
52 Week high$49.67
52 Week low
$15.86
52 Week low$15.86

Stock Snapshot

As of today, UroGen Pharma(URGN) shares are valued at $48.12. The company's market cap stands at 2.99B, with a P/E ratio of -24.13.

As of 2026-08-14, UroGen Pharma(URGN) stock has fluctuated between $47.67 and $49.60. The current price stands at $48.12, placing the stock +0.9% above today's low and -3.0% off the high.

UroGen Pharma(URGN) shares are trading with a volume of 859.71K, against a daily average of 1.12M.

During the past year, UroGen Pharma(URGN) stock moved between $15.86 at its lowest and $49.67 at its peak.

During the past year, UroGen Pharma(URGN) stock moved between $15.86 at its lowest and $49.67 at its peak.

URGN News

Simply Wall St 3d
UroGen Pharma Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?

UroGen Pharma’s recently reported Q2 2026 results showed sales rising to US$72.46 million from US$24.22 million a year earlier, while net loss narrowed to US$14...

UroGen Pharma Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own URGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.